MariMed Inc. (MRMD.CN)
| Previous Close | 0.3200 |
| Open | 0.3500 |
| Bid | 0.3050 x N/A |
| Ask | 0.3700 x N/A |
| Day's Range | 0.3050 - 0.3500 |
| 52 Week Range | 0.2000 - 0.7800 |
| Volume | |
| Avg. Volume | 28,792 |
| Market Cap | 143.284M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings Date | Jul 31, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Insider MonkeyMariMed Inc. (PNK:MRMD) Q1 2024 Earnings Call Transcript
MariMed Inc. (PNK:MRMD) Q1 2024 Earnings Call Transcript May 9, 2024 MariMed Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Alan and I’ll be your conference operator today. At this time, I would like […]
GlobeNewswireMariMed Reports First Quarter 2024 Earnings
NORWOOD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQX: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2024. “With the first quarter now in the books, I’m pleased to say we are on track with our strategic plan and financial targets,” said Jon Levine, Chief Executive Officer. “The tremendous growth in our wholesale business was un
- GlobeNewswire
Statement From MariMed CEO And President Jon Levine Regarding The Drug Enforcement Administration’s Decision To Recategorize Cannabis To Schedule III
NORWOOD, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- The following is a statement from Jon Levine, CEO and President of leading multi-state cannabis operator, MariMed Inc. (“MariMed”) (CSE: MRMD) (OTCQX: MRMD). “The impending announcement of the DEA’s decision to recategorize cannabis from Schedule I to Schedule III under the Controlled Substances Act is historic. The positive impact this will have cannot be overstated. Our industry, the millions of consumers and patients we serve, and the individ
